The global vaccines market is estimated at $41bn in 2018 and is expected to grow at a CAGR of 10.9% during the forecast period. The Paediatric Vaccines segment held 56% of the Global Vaccines market in 2018.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 201-page report you will receive 121 charts– all unavailable elsewhere.
The 201-page report provides clear detailed insight into the global vaccines sales market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Vaccines Sales Market forecasts from 2019-2029
• Global Vaccines Sales Market forecasts from 2019-2029 by Submarket:
• Paediatric Vaccines
• Adult Vaccines
• Elderly Vaccines
• Travel Vaccines
• Therapeutic Vaccines
• Global Vaccines Sales Market forecasts from 2019-2029 by Leading Vaccines:
• Prevnar
• Gardasil
• Fluzone
• Pentacel
• ProQuad
• Infanrix/Pediarix
• Zostavax
• RotaTeq
• Hepatitis Vaccines
• Menactra
• Global Vaccines Sales Market forecasts from 2019-2029 by Regional and National Market:
• US
• EU5: Germany, France, Italy, UK, Spain
• Japan
• Brazil
• Russia
• India
• China
• Profiles of the selected leading companies:
• AstraZeneca
• Eli Lilly
• Emergent BioSolutions Inc.
• GlaxoSmithKline
• Johnson & Johnson
• Merck & Co.
• Pfizer
• Sanofi
• Serum Indian Institute Pvt. Ltd.
• Takeda
• The Vaccines Market Pipeline Analysis
• A SWOT and STEP analysis of the global vaccines market
• Key Questions Answered by this Report:
• What is the current size of the overall global human vaccines market? How much will this market be worth from 2018 to 2029?
• What are the main drivers and restraints that will shape the overall vaccines market over the next ten years?
• What are the main segments within the overall human vaccines market? How much will each of these segments be worth for the period 2018 to 2029? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2028?
• How will political and regulatory forces influence regional markets?
• How will market shares of the leading national markets change by 2029, and which geographical region will lead the market in 2029?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are the leading vaccines? What are their revenues and latest developments?
• What are some of the most prominent human vaccines currently in development?
• What are the main trends that will affect the world vaccines market between 2018 and 2029?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global vaccines market evolve over the forecasted period, 2018 to 2029?
• How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029?
• Which therapies can succeed and what revenues could they generate to 2029?
• What will be the main commercial drivers for the market from 2018 to 2029?
• How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
• How will that industry evolve between 2018 and 2029, especially in R&D?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Vaccines Sales Market. You find data, trends and predictions.
Buy our report today Global Vaccines Sales Market Analysis : Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Overview of the World Vaccines Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to the World Human Vaccines Market
2.1 Human Vaccines - Aiming for Global Disease Prevention
2.2 What is the Social and Economic Burden?
2.3 Vaccine Technology
2.3.1 Inactivated Vaccines
2.3.2 Live Attenuated Vaccines
2.3.3 Conjugate Vaccines
2.3.4 Recombinant Vector Vaccines
2.4 Key Influencers of the Human Vaccine Market
2.4.1 Governments and International Organizations
2.4.1.1 The World Health Organisation (WHO)
2.4.1.2 The Governmental Influence
2.4.2 Leading Manufacturers
2.4.2.1 Merck& Co.
2.4.2.2 Sanofi
2.4.2.3 GlaxoSmithKline
2.4.2.4 Pfizer
2.5 Human World Vaccines – Market Segmentation
2.5.1 Paediatric Vaccines
2.5.2 Adult Vaccines
2.5.3 Elderly Vaccines
2.5.4 Travel Vaccines
2.5.5 Therapeutic Vaccines
3. World Vaccine Market Outlook, 2019-2029
3.1 World Vaccine Market, 2018
3.1.1 Paediatric Vaccines Maintains Constant Demand
3.1.2 Ageing Population Requires More Care
3.1.3 Emerging Markets Demand Better Immunity
3.2 The World Human Vaccines Forecast, 2019-2029
3.3 The World Vaccine Market: Industry Trends
3.3.1 Undulating Demand
3.3.2 Supply Restraints
3.3.3 Funding Trends
3.3.4 Protecting the Workforce of an Economy
4. World Vaccine Submarkets: Prospects, 2019-2029
4.1 Paediatric Vaccines
4.1.1 Paediatric Vaccine Forecast, 2019-2029
4.1.2 Paediatric Vaccine Trends
4.1.2.1 Innovative Delivery
4.1.2.2 Fear Factor
4.1.2.3 Novel Vectors
4.2 Adult Vaccines
4.2.1 Adult Vaccine Forecast, 2019-2029
4.2.2 Adult Vaccine Trends
4.2.2.1 Fighting the Flu
4.2.2.2 HPV
4.2.2.3 Repeat Doses for Continued Protection
4.3 Elderly Vaccines
4.3.1 Elderly Vaccine Forecast, 2019-2029
4.3.2 Elderly Vaccine Trends
4.3.2.1 With Age Comes Greater Risk
4.3.2.2 Ageing Population across the Globe
4.4 Travel Vaccines
4.4.1 Travel Vaccines Forecast, 2018-2029
4.4.2 Travel Vaccine Trends
4.4.2.1 Zika Virus Outbreak
4.4.2.2 Globalization Carries Diseases
4.5 Therapeutic Vaccines
4.5.1 Therapeutic Vaccine Trends
5. Leading Vaccines: Revenue Forecasts, 2019-2029
5.1 Prevnar (Pfizer) - Pneumococcal Pneumonia
5.2 Gardasil (Merck & Co.) - HPV
5.3 Fluzone (Sanofi) – Influenza
5.4 Pentacel (Sanofi) – DtaP, Polio, HiB
5.5 ProQuad / M-M-R II / Varivax (Merck and Co.) – Varicella/Chickenpox, Measles, Mumps, Rubella.
5.6 Infanrix/Pediarix (GSK) – Diptheria, Tetanus and Acellular Pertussis
5.7 Zostavax (Merck and Co.) – Herpes
5.8 RotaTeq (Merck and Co.) – Rotavirus
5.9 Hepatitis Vaccines (GSK) – Hepatitis A & B
5.10 Menactra (Sanofi) – Meningococcal
6. Regional and Leading Developed National Vaccines Markets, 2019-2029
6.1 North America Vaccine Market, 2019-2029
6.1.1 The US Vaccine Market, 2018
6.1.2 The US Vaccine Market Forecast, 2019-2029
6.2 Japanese Vaccine Market, 2019-2029
6.2.1 The Japanese Vaccine Market, 2018
6.2.2 The Japanese Vaccine Market Forecast, 2019-2029
6.2.3 Addressing the Alleged Vaccine Gap
6.3 EU5 Vaccine Market, 2019-2029
6.3.1 The EU5 Vaccine Market, 2018
6.3.2 The EU5 Vaccine Market Forecast, 2019-2029
6.4 United Kingdom Vaccine Market, 2019-2029
6.4.1 The UK Vaccine Market, 2018
6.4.2 The UK Vaccine Market Forecast, 2019-2029
6.5 France: Vaccine Market, 2019-2029
6.5.1 The French Vaccine Market, 2018
6.5.2 The French Vaccine Market Forecast, 2019-2029
6.5.3 French Healthcare System – Immunization Policy
6.6 Germany: Vaccine Market, 2019-2029
6.6.1 The German Vaccine Market, 2018
6.6.2 The German Vaccine Market Forecast, 2019-2029
6.7 Italy: Vaccine Market, 2019-2029
6.7.1 The Italian Vaccine Market, 2018
6.7.2 The Italian Vaccine Market Forecast, 2019-2029
6.7.3 Challenges in Public Healthcare
6.8 Spain: Vaccine Market, 2019-2029
6.8.1 The Spanish Vaccine Market, 2018
6.8.2 The Spanish Vaccine Market Forecast, 2019-2029
6.8.3 District Rules – Economic Challenges
7. Leading Emerging National Markets, 2019-2029
7.1 China: Vaccine Market, 2019-2029
7.1.1 The Chinese Vaccine Market, 2018
7.1.2 The Chinese Vaccine Market Forecast, 2019-2029
7.1.3 Setting-Up Domestic Vaccine Industries
7.2 India: Vaccine Market, 2019-2029
7.2.1 The Indian Vaccine Market, 2018
7.2.2 The Indian Vaccine Market Forecast, 2019-2029
7.2.3 The Extent to which the Vaccine Market Can Flourish?
7.3 Brazil: Vaccine Market, 2019-2029
7.3.1 The Brazilian Vaccine Market, 2018
7.3.2 The Brazilian Vaccine Market Forecast, 2019-2029
7.3.3 Zika Outbreak
7.4 Russia: Vaccine Market, 2019-2029
7.4.1 The Russian Vaccine Market, 2018
7.4.2 The Russian Vaccine Market Forecast, 2019-2029
7.4.3 Power of the State
8. Leading Manufacturers of Vaccines for Human Use
8.1 GlaxoSmithKline (GSK)
8.1.1 GSK Vaccine Performance
8.1.2 GSK Developments
8.1.2.1 Mergers and Acquisitions
8.1.2.2 GSK Vaccine Pipeline
8.2 Merck& Co.
8.2.1 Merck Vaccine Performance
8.2.2 Merck Developments
8.2.2.1 Merck Market Movements
8.2.2.2 Collaborations
8.2.2.3 Merck Pipeline
8.3 Sanofi
8.3.1 Sanofi Vaccine Performance
8.3.2 Sanofi Developments
8.3.2.1 Acquisitions & Expansions
8.3.2.2 Sanofi Vaccine Pipeline
8.4 Pfizer
8.4.1 Pfizer Vaccine Performance
8.4.1.1 Financial Overview
8.4.2 Pfizer Developments
8.4.2.1 Pfizer Mergers & Acquisitions
8.4.2.2 Pfizer Pipeline
8.5 Johnson & Johnson
8.5.1 Financial Overview
8.6 AstraZeneca
8.6.1 Financial Overview
8.7 Eli Lilly and Company
8.7.1 Eli Lilly and Company Vaccine Performance
8.7.1.1 Financial Overview
8.7.2 Eli Lilly and Company Developments
8.8 Takeda Pharmaceutical Company Limited
8.8.1 Takeda Pharmaceutical Company Limited Vaccine Performance
8.8.1.1 Financial Overview
8.9 Serum Institute of India Private Limited
8.9.1 Serum Institute of India Private Limited Vaccine Performance
8.10 Emergent BioSolutions Inc.
8.10.1 Emergent BioSolutions Inc. Vaccine Performance
8.11 Key Strategic Acquisitions and Collaborations
8.12 Other Companies Serving the Vaccines Market
9. Research & Development, 2018
9.1 Prophylactic Vaccines R&D Pipeline
9.1.1 Paediatric Vaccines R&D Pipeline
9.1.2 Adult Vaccines R&D Pipeline
9.1.3 Elderly Vaccines R&D Pipeline
9.1.4 Travel Vaccines R&D Pipeline
9.2 Therapeutic Vaccines R&D Pipeline
10. Qualitative Analysis of the World Vaccines Market
10.1 SWOT Analysis of the World Human Vaccines Market
10.1.1 Strengths
10.1.1.1 Ageing Population
10.1.1.2 Prevention is Better than Cure
10.1.1.3 Demand from Emerging Markets Continue
10.1.1.4 Promising R&D Pipeline
10.1.1.5 Increasing Awareness
10.1.2 Weaknesses
10.1.2.1 High Manufacturing Costs
10.1.2.2 Time Constraints
10.1.2.3 Barriers to Market Entry
10.1.3 Opportunities
10.1.3.1 Constant Improvements in Vaccine Technology and Delivery Methods
10.1.3.2 Shifting Focus on Adults Vaccines
10.1.4 Threats
10.1.4.1 Oligarchic Presence of Pharmaceutical Giants
10.1.4.2 Productivity Gap
10.2 STEP Analysis of the World Human Vaccines Industry and Market
10.2.1 Social Factors
10.2.1.1 Maintaining a Healthier Workforce
10.2.1.2 Public Hesitation - Fear of Unwanted Side-Effects
10.2.2 Technological Forces
10.2.2.1 Evolution of Vaccine Technology Pave the Way for Prophylactics and Therapeutics
10.2.3 Economic Factors
10.2.3.1 High Costs of Production
10.2.3.2 Soaring Vaccines Demand from Developing Countries
10.2.4 Political Factors
10.2.4.1 Governments Play Crucial Roles in Vaccination
11. Conclusions
11.1 Segment Market Share Shift
11.2 Elderly People Become the New Target Market
11.3 Endemic Infections Drive Travel Vaccines Growth
11.4 Emerging Markets: High Demand for Vaccines
11.5 Demand in Mature Pharma Markets Continues: in Particular Japan Will Show Sales Growth
11.6 Strong and Diverse Research and Development
11.7 Concluding Remarks
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 3.1 The Global Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGRs (%), 2019-2029
Table 4.1 World Vaccines Submarkets: Revenue Forecasts ($bn), AGR (%), CAGR (%), 2019-2029
Table 4.2 World Vaccines Submarkets: Market Shares (%), 2017-2029
Table 4.3 World Paediatric Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 4.4 World Adult Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 4.5 World Elderly Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 4.6 World Travel Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 5.1 Prevnar Revenue ($bn), 2014-2017
Table 5.2 Prevnar Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 5.3 Gardasil Revenue ($bn), 2014-2017
Table 5.4 Gardasil Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 5.5 Fluzone/Vaxigrip: Revenue ($bn), 2014-2017
Table 5.6 Fluzone Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 5.7 Pentacel Revenue ($bn), 2014-2017
Table 5.8 Pentacel Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 5.9 ProQuad / M-M-R II / Varivax Revenue ($bn), 2014-2017
Table 5.10 ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 5.11 Infanrix/Pediarix Revenue ($bn), 2014-2016
Table 5.12 Infanrix/Pediarix Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 5.13 Zostavax Revenue ($bn), 2014-2017
Table 5.14 Zostavax Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 5.15 RotaTeq Revenue ($bn), 2014-2017
Table 5.16 RotaTeq Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 5.17 GSK Hepatitis Vaccines Revenue ($bn), 2014-2016
Table 5.18 GSK Hepatitis Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2018-2029
Table 5.19 Menactra Revenue ($bn), 2014-2017
Table 5.20 Menactra Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2018-2029
Table 6.1 Leading National Market Revenue Forecasts ($bn), 2018, 2023, 2029
Table 6.2 Leading Developed National Markets Revenue Forecasts ($bn), 2018, 2023, 2029
Table 6.3 Leading Developed National Market Shares (%), 2018, 2023, 2029
Table 6.4 North America Vaccines Revenue Forecast by Submarket ($bn), Annual Growth (%) and CAGR (%), 2019-2029
Table 6.5 North America Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029
Table 6.6 The US Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029
Table 6.7 The Japanese Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 6.8 Europe Vaccines Revenue Forecast by Submarkets ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 6.9 Europe Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2019-2029
Table 6.10 The EU5 Vaccines World Market Shares (%), 2018, 2023, 2029
Table 6.11 EU5 Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 6.12 The UK Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 6.13 The French Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 6.14 The German Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 6.15 The Italian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 6.16 The Spanish Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 7.1 Asia-Pacific Vaccines Revenue Forecast by Submarket ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 7.2 Asia-Pacific Vaccines Revenue Forecast, By Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029
Table 7.3 Leading Emerging National Market Revenue Forecasts ($bn), 2018, 2023, 2029
Table 7.4 Leading Emerging National Market Shares (%), 2018, 2023, 2029
Table 7.5 The Chinese Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
Table 7.6 The Indian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029
Table 7.7 The Brazilian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029
Table 7.8 The Russian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share and CAGR (%), 2019-2029
Table 9.1 Prophylactic Vaccines in Development, 2018
Table 9.2 Paediatric Vaccines in Development, 2018
Table 9.3 Adult Vaccines in Development, 2018
Table 9.4 Elderly Vaccines in Development, 2018
Table 9.5 Travel Vaccines in Development, 2018
Table 9.6 Therapeutic Vaccines in Development, 2018
List of Figures
Figure 1.1 World Vaccines Market Segmentation, 2017
Figure 3.1 Vaccines Market Share within Global Pharmaceutical Market (%), 2018
Figure 3.2 World Vaccines Leading National Market Shares (%), 2018
Figure 3.3 World Vaccines Leading National Market Shares (%), 2023
Figure 3.4 World Vaccines Leading National Market Shares (%), 2029
Figure 3.5 World Vaccines Market: Drivers and Restraints
Figure 4.1 World Vaccines Submarket (%) Segmentation, 2018
Figure 4.2 World Paediatric Vaccines Market Share (%), 2019
Figure 4.3 World Paediatric Vaccines Market Share (%), 2023
Figure 4.4 World Paediatric Vaccines Market Share (%), 2029
Figure 4.5 World Paediatric Vaccines Revenue Forecast ($bn), 2019-2029
Figure 4.6 World Adult Vaccines Market Share (%), 2019
Figure 4.7 World Adult Vaccines Market Share (%), 2023
Figure 4.8 World Adult Vaccines Market Share (%), 2029
Figure 4.9 World Adult Vaccines Revenue Forecast ($bn), 2019-2029
Figure 4.10 World Elderly Vaccines Market Share (%), 2019
Figure 4.11 World Elderly Vaccines Market Share (%), 2023
Figure 4.12 World Elderly Vaccines Market Share (%), 2029
Figure 4.13 World Elderly Vaccines Revenue Forecast ($bn), 2019-2029
Figure 4.14 World Travel Vaccines Market Share (%), 2019
Figure 4.15 World Travel Vaccines Market Share (%), 2023
Figure 4.16 World Travel Vaccines Market Share (%), 2029
Figure 4.17 World Travel Vaccines Revenue Forecast ($bn), 2019-2029
Figure 5.1 Prevnar Revenue Forecast ($bn), 2019-2029
Figure 5.2 Gardasil Revenue Forecast ($bn), 2019-2029
Figure 5.3 Fluzone Revenue Forecast ($bn), 2019-2029
Figure 5.4 Pentacel Revenue Forecast ($bn), 2019-2029
Figure 5.5 ProQuad / M-M-R II / VarivaxRevenue Forecast ($bn), 2019-2029
Figure 5.6 Infanrix/Pediarix Revenue Forecast ($bn), 2019-2029
Figure 5.7 Zostavax Revenue Forecast ($bn), 2019-2029
Figure 5.8 RotaTeq Revenue Forecast ($bn), 2019-2029
Figure 5.9 GSK Hepatitis Vaccines Revenue Forecast ($bn), 2019-2029
Figure 5.10 Menactra Revenue Forecast ($bn), 2019-2029
Figure 6.1 The US Vaccines Revenue Forecast ($bn), 2019-2029
Figure 6.2 The Japanese Vaccines Revenue Forecast ($bn), 2019-2029
Figure 6.3 EU5 Vaccines Market Share (%), 2018
Figure 6.4 EU5 Vaccines Market Share (%), 2023
Figure 6.5 EU5 Vaccines Market Share (%), 2029
Figure 6.6 The UK Vaccines Revenue Forecast ($bn), 2019-2029
Figure 6.7 The French Vaccines Revenue Forecast ($bn), 2019-2029
Figure 6.8 The German Vaccines Revenue Forecast ($bn), 2019-2029
Figure 6.9 The Italian Vaccines Revenue Forecast ($bn), 2019-2029
Figure 6.10 The Spanish Vaccines Revenue Forecast ($bn), 2019-2029
Figure 7.1 BRIC Countries Vaccines Market Share (%), 2018
Figure 7.2 BRIC Countries: Vaccines Market Share (%), 2023
Figure 7.3 BRIC Countries: Vaccines Market Share (%), 2029
Figure 7.4 The Chinese Vaccines Revenue Forecast ($bn), 2019-2029
Figure 7.5 The Indian Vaccines Revenue Forecast ($bn), 2019-2029
Figure 7.6 The Brazilian Vaccines Revenue Forecast ($bn), 2019-2029
Figure 7.7 The Russian Vaccines Revenue Forecast ($bn), 2019-2029
Figure 8.1 GSK Vaccines Revenue ($bn), 2015-2017
Figure 8.2 GSK Vaccines Region Breakdown (%), 2017
Figure 8.3 Merck Vaccines Revenue (%), 2017
Figure 8.4 Sanofi Vaccines Revenue ($bn), 2014-2017
Figure 8.5 Pfizer Revenue ($bn), 2014-2017
Figure 8.6 J&J Revenue ($bn), 2014-2017
Figure 8.7 AstraZeneca Revenue ($bn), 2014-2017
Figure 8.8 Eli Lilly and Company Revenue ($bn), 2014-2017
Figure 8.9 Takeda Pharmaceutical Revenue ($bn), 2014-2017
Figure 10.1 SWOT Analysis of the World Vaccines Market
Figure 10.2 STEP Analysis of the World Vaccines Market
Figure 11.1 World Paediatric Vaccines Revenue Forecast ($bn), 2018-2029
Figure 11.2 World Elderly Vaccines Revenue Forecast ($bn), 2018-2029
Figure 11.3 Asia-Pacific Vaccines Revenue Forecast (% Share), 2018-2029
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
